ArticleScientific reports2026
Exploration of m7G-related immune genes and construction of a prognostic risk model in gastric cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Gastric cancer (GC) is a lethal digestive malignancy with poor outcomes. Although N7-Methylguanosine (m7G) modification and immune-related genes (IRGs) individually affect GC prognosis and the tumor microenvironment, their mechanistic crosstalk remains unclear. Differentially expressed genes (DEGs) in GC were identified and used alongside m7G-related genes (m7G-RGs) to perform consensus clustering, defining molecular subtypes and yielding additional DEGs. Intersection of these gene sets identified m7G-related immune genes. Prognostic genes were selected via Least Absolute Shrinkage and Selection Operator (LASSO), and Cox regression analysis to construct a validated prognostic risk model. Associations between clinicopathological features and risk scores were assessed, identifying independent prognostic factors and enabling nomogram development. The risk-stratified groups underwent gene set enrichment analysis (GSEA), immune infiltration, tumor immune dysfunction and exclusion (TIDE), tumor purity, drug sensitivity, and tumor mutation burden (TMB) analyses. Using GC and normal samples, this study identified 4,458 DEGs. Intersection with subtype-specific DEGs (2,098) and immune genes (4,172) yielded 193 m7G-associated immune genes. Six prognostic genes (ELANE, ASCL2, APOA1, GRP, CD36, MUC15) were used to construct a prognostic risk model that stratified patients into high- and low-risk groups with significant survival differences and strong predictive accuracy. Age, stage, and risk score were independent prognostic factors, and a nomogram was developed. High-risk patients showed enrichment in tumor-promoting pathways (e.g., calcium signaling), immunosuppressive microenvironments, higher stromal scores, and TP53 mutations. Low-risk patients had activated DNA repair pathways, lower TIDE scores, higher immune infiltration, and TTN mutations. Drug sensitivity analysis identified 130 compounds with differential responses between groups (p < 0.05). This study developed a robust prognostic risk model based on six prognostic genes, which effectively reveals molecular mechanisms and immune features of GC, offering a foundation for individualized therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.